LAUSANNE, Switzerland--(BUSINESS WIRE)--Neo Medical SA (Neo), a Swiss technology company specializing in spine surgery, has announced the successful completion of its Series B financing round, including the conversion of existing shareholder loans. With this financing round, Neo has secured an additional equity investment of up to $68 million (CHF 58 million) to accelerate its global growth..

瑞士洛桑--（商业新闻短讯）--专门从事脊柱手术的瑞士技术公司Neo Medical SA（Neo）宣布成功完成其B轮融资，包括转换现有股东贷款。通过这轮融资，Neo获得了高达6800万美元（5800万瑞士法郎）的额外股权投资，以加速其全球增长。

Led by Gyrus Capital SA (Gyrus), alongside the participation of existing investors, including founders Vincent Lefauconnier and Jonas Larsson, this landmark round is one of the most significant in the spine industry in the last decade.

由Gyrus Capital SA（Gyrus）领导，现有投资者（包括创始人文森特·莱福康尼尔（Vincent Lefauconnier）和乔纳斯·拉尔森（Jonas Larsson））参与，这一里程碑式的回合是过去十年脊柱行业最重要的一轮。

The proceeds will be used to increase Neo’s market share in key regions with an immediate focus on expanding the US business, deploying new, complementary, and disruptive products, and enhancing the capabilities of its unique AI-driven augmented reality intraoperative data platform, ADVISE™. With ADVISE™, the company’s portfolio of advanced surgical technologies - Neo Universal™ - represents a significant step forward for the $7.6 billion global thoracolumbar fusion market..

收益将用于增加Neo在关键地区的市场份额，并立即专注于扩展美国业务，部署新的，互补的和破坏性的产品，以及增强其独特的AI驱动的增强现实术中数据平台ADVISE™的能力。凭借ADVISE™，该公司的先进外科技术组合-Neo Universal™-为全球76亿美元的胸腰椎融合术市场迈出了重要的一步。

“Thoracolumbar spine surgery is a large market that has lacked disruptive innovation for decades – the spine sector needs innovation to improve patient outcomes and drive positive change for all stakeholders,” said Vincent Lefauconnier, Neo Medical’s CEO and Co-Founder. “This is precisely what we have set out to achieve with Neo Universal™ – a platform introducing new technological and structural approaches to create real value both inside and outside the operating theatre.

Neo Medical首席执行官兼联合创始人文森特·莱福康尼尔（Vincent Lefauconnier）表示：“胸腰椎手术是一个巨大的市场，几十年来一直缺乏颠覆性创新，脊柱行业需要创新来改善患者的预后，并为所有利益相关者带来积极的变化。”。“这正是我们计划通过Neo Universal™实现的目标，Neo Universal™是一个引入新技术和结构方法的平台，可在手术室内外创造真正的价值。

After successfully entering key markets, we are ready to scale. This funding will enable us to grow and push the boundaries of what is possible in spine surgery, bringing our solutions to more healthcare providers and, most importantly, improving outcomes for patients.”.

成功进入关键市场后，我们准备扩大规模。这笔资金将使我们能够发展并推动脊柱手术的发展，将我们的解决方案带给更多的医疗保健提供者，最重要的是，改善患者的预后。”

“Neo Medical’s vision and product platform has already proven itself in Europe and is poised to expand rapidly in the US,” said Dr. Robert Watson, Partner and Co-Founder of Gyrus. “The sustainable commercialization of Neo’s integrated portfolio of technologies and innovative service model strategically positions the company to scale and capitalize on evolving market trends, including within outpatient centers.

Gyrus合伙人兼联合创始人罗伯特·沃森博士表示：“Neo Medical的愿景和产品平台已经在欧洲证明了自己，并准备在美国迅速扩张。”

We are excited to partner with the management team and support Neo’s vision in redefining patient care.”.

我们很高兴与管理团队合作，并支持Neo在重新定义患者护理方面的愿景。”

Since commercial launch in 2016, Neo’s technologies have been used to treat around 36,000 patients, with the company making significant progress in both operational and clinical performance compared to traditional standards. Studies have shown Neo’s products can cut implant failure rates by up to three-times, infection risk by half, and time spent in surgery by up to 29%, reducing the need for revisionary surgery by as much as 50%.1-3.

自2016年商业启动以来，Neo的技术已被用于治疗约36000名患者，与传统标准相比，该公司在操作和临床表现方面取得了重大进展。研究表明，Neo的产品可以将植入失败率降低三倍，感染风险降低一半，手术时间减少29%，修复手术的需要减少多达50%。

Mr. Lefauconnier went on to say, 'This raise is the next step in solidifying Neo Universal™ as one of the premier solutions on the market. Intended to treat thoracolumbar patients in inpatient and outpatient settings, it supports both MIS and open approaches. Launching extended capabilities for complex surgery will soon optimize our platform coverage from ambulatory surgery to ever more complex trauma and deformity.”.

。旨在在住院和门诊治疗胸腰椎患者，它支持MIS和开放式方法。启动复杂手术的扩展功能将很快优化我们的平台覆盖范围，从门诊手术到更复杂的创伤和畸形。”

About Neo Medical

关于Neo Medical

Neo Medical is a Swiss company combining the latest advances in biomechanics and intraoperative augmented reality to set new standards in spine fusion surgery.

Neo Medical是一家瑞士公司，结合生物力学和术中增强现实技术的最新进展，为脊柱融合手术制定新标准。

Uniquely designed to support treatment of any operable thoracolumbar condition in a single procedural platform, the company’s portfolio seamlessly integrates proprietary force control technologies with first-of-its-kind, intraoperative, AI-driven augmented reality data capabilities to improve patient outcomes, reduce environmental impacts, and lower healthcare-associated costs..

该公司的产品组合专门设计用于在单一程序平台上支持任何可操作的胸腰椎疾病的治疗，将专有的力控制技术与首创的术中人工智能驱动的增强现实数据功能无缝集成，以改善患者预后，减少环境影响，并降低医疗保健相关成本。

Coupling its technologies with a 'SmartService’ distribution model, Neo Medical’s services optimize processes in and out of the OR, enhancing operational efficiency at every stage of the perioperative process, and contributing to a more sustainable healthcare system.

Neo Medical的服务将其技术与“智能服务”分销模式相结合，优化手术室内外的流程，提高围手术期流程每个阶段的运营效率，并为更可持续的医疗保健系统做出贡献。

With a strong European presence and proven leadership, the Company is rapidly expanding in the U.S. and elsewhere around the globe. Based near Lausanne, Switzerland, Neo Medical has operating subsidiaries in the US, Spain, France, and Germany. In addition to the lead investor Gyrus, its shareholding base includes institutional players such as Swisscom Ventures, Verve Ventures, 4FO, and Credit Suisse Entrepreneur Capital.

凭借强大的欧洲影响力和成熟的领导力，该公司正在美国和全球其他地方迅速扩张。Neo Medical总部位于瑞士洛桑附近，在美国、西班牙、法国和德国设有运营子公司。除了主要投资者Gyrus外，其持股基础还包括Swisscom Ventures、Verve Ventures、4FO和瑞士信贷创业资本等机构参与者。

To learn more, please visit www.neo-medical.com..

欲了解更多信息，请访问www.neo-medical.com。。

About Gyrus Capital

关于Gyrus Capital

Gyrus Capital is a European investment firm dedicated to transformational investments in the healthcare and sustainability sectors. Based in Geneva, Switzerland, Gyrus invests in businesses that address the structural needs of society and the environment and are positioned for long-term sustainable growth.

Gyrus Capital是一家欧洲投资公司，致力于医疗保健和可持续发展领域的转型投资。Gyrus总部位于瑞士日内瓦，投资于满足社会和环境结构性需求的企业，并为长期可持续增长做好准备。

The firm focuses on complex transactions, particularly corporate carve-outs in the €50 million to €500 million range. A renowned group of experienced partners and industry experts supports Gyrus’s active investment and value-creation approach, working closely with entrepreneurs and managers. To learn more, please visit www.gyruscapital.com..

该公司专注于复杂的交易，尤其是5000万欧元至5亿欧元范围内的企业分拆。一批经验丰富的知名合作伙伴和行业专家支持Gyrus的积极投资和价值创造方法，并与企业家和管理者密切合作。欲了解更多信息，请访问www.gyruscapital.com。

References:

参考文献：

https://neo-medical.com/press-release-references-1d9e0z/

https://neo-medical.com/press-release-references-1d9e0z/